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Introduction. For decades, transurethral resection of the prostate (TURP) has been the “gold standard” operation for benign
prostatic hyperplasia (BPH) but is based mainly on historic data. The historic data lacks use of validated measures and current
TURP diﬀers signiﬁcantly from that performed 30 years ago. Methods. Men who had undergone TURP between 2001 and 2005
were reviewed. International prostate symptom score (IPSS), quality of life (QOL) and peak urinary ﬂow rate (Qmax), and postvoid
residual (PVR) were recorded. Operative details and postoperative complications were documented. Patients were then invited
to attend for repeat assessment. Results. 91 patients participated. Mean follow-up time was 70 months. Mean follow-up results
were IPSS—7; QoL—1.5; Qmax—23mL/s; PVR—45mL. These were an improvement from baseline of 67%, 63%, 187%, and
80%, respectively. Early complication rates were low, with no blood transfusions, TUR syndrome, or deaths occurring. Urethral
strictureratewas higherthananticipated at14%.Conclusion.ThisstudyshowsmodernTURPstillproducesdurableimprovement
in voiding symptoms which remains comparable with historic studies. This study, however, found a marked drop in early
complications but, conversely, a higher than expected incidence of urethral strictures.
1.Introduction
Benign prostatic hyperplasia (BPH) is common in men,
ranging from 50% in 50 year olds to 90% in 90 year
olds. Around 50% of men develop irritating symptoms
summarised generally as lower urinary tract symptoms
(LUTS).
For decades, TURP has been the “gold standard” surgical
intervention for LUTS associated with BPH. The persis-
tence of traditional diathermy endoscopic prostatectomy as
the preferred surgical treatment option for BPH, despite
newer technologies constantly being introduced, is based
on the belief that outcomes are durable. The evidence that
this belief is based on however is now mainly historic
[1–4].
AlthoughTURPhasbeenaroundfordecades,thecurrent
operation diﬀers signiﬁcantly from that performed 30 years
ago. There have been improvements in operative technique,
instrument technology, and anaesthetic methods. TURP is
now safer, with a much lower mortality rate reported, but
the eﬀect these changes have had on long-term outcomes is
largely unknown [5, 6].
Recent literature on endoscopic, diathermy, prostatec-
tomy focuses either on technical changes or is comparative
studies with associated limitations. Recent long-term studies
(>3 year) which include TURP use the procedure as the
control arm. With these types of studies they typically have
small patient groups and adopt strict inclusion criteria (i.e.,
prostate size restrictions [7–12]) that may render the study
sample unrepresentative of the general TURP patient cohort.
Another limitation of older studies is that many were
performed in the 1980’s and early 90’s [1–5]. These studies
typically use retrospective registry data and nonstandard-
ised survey instruments. The IPSS and IIEF only emerged
in the late 1990’s. This makes comparison with current data
diﬃcult. Updated data is needed.2 Advances in Urology
The aim of this study therefore was to assess the long-
termclinicaloutcomesfollowingTURPinaverageAustralian
males.
2. Methods
Human Research Ethics Committee (HREC) approval was
gained to allow access to men who had undergone TURP
between 2001 and 2005 by a single senior urological surgeon.
Patientswereidentiﬁedfromthepracticecomputerdatabase.
All eligible ﬁles were reviewed. Patients who had or
subsequently developed prostate cancer, invasive urothelial
carcinoma, or neurogenic bladders were excluded. Men who
had undergone previous prostate- or urethra-related surgery
were also excluded.
Eligible patients were posted an HREC-approved partici-
pant information letter inviting them for further assessment.
If failing to respond, a second letter was sent after checking
addresses with their general practitioner. A second failure
to respond was deemed a refusal to participate. Subjects
that were willing to participate had their ﬁles reviewed and
baseline data collected.
Fileswereinitiallyreadtoidentifyeligiblesubjects.When
a subject was deemed eligible their notes were reviewed
for baseline data. Baseline data included preoperative inter-
national prostate symptom score (IPSS), quality of life
(QOL) score, and international index of erectile function
(IIEF-5).Peakurinaryﬂowrate(Qmax),voidedvolume(VV),
and postvoid residual (PVR) were documented except for
patients in acute urinary retention. If available, prostate-
speciﬁc antigen (PSA) within one year before surgery was
also recorded.
Operation reports were read to conﬁrm operation date
and that standard operating procedure had been followed
with no other intervention, other than insertion of supra-
pubic catheter (SPC), being conducted. Prostate tissue
resection weight was documented. Postoperative incidence
of blood transfusion, TUR syndrome, and death were also
documented.
Patients were then invited to attend an interview, and
repeat assessment was conducted. Patients were asked specif-
ically about any urinary tract intervention since their opera-
tion, and if any had occurred, they were classiﬁed as treat-
ment failure and excluded from repeat assessment. Repeat
assessment involved completing the IPSS, QoL, IIEF-5, and
patient global impression of improvement score (PGI-I)
questionnaires. Sexually active patients were questioned on
the presence or absence of antegrade seminal emission with
ejaculation. Qmax, VV, and PVR were measured. A voided
volume of at least 125mL was required before a ﬂow rate
was considered valid. PVR was assessed using an ultrasound
bladder scanner.
When possible, data was analysed as paired data. Men
who were in acute urinary retention before the operation
were excluded from paired data analysis. Statistical analysis
was performed using Wilcoxon signed ranks test for paired
analyses. Two-tailed statistical signiﬁcance was considered at
the 5% level. SPSS statistical software program was used.
Table 1: Treatment failure post-TURP.
Reason for failure Number
Urethral strictures 13
Bladder neck contractures 2
Prostatic regrowth 4
Detrusor failure 3
Total∗ 19
∗Three patients had two complications.
3. Results
210 patients undertook TURP between 2001 and 2005. 24
had prior prostate surgery, 38 prostate cancer, and 3 invasive
bladder cancer resulting in 65 patients being excluded.
Another 19 patients had died (causes unrelated to
the prostate surgery), 24 lost to follow up, 5 unwilling
participants, and 6 lived too far away. This left 91 patients
available for long-term outcome review.
Of the 91 men who underwent long-term review, 19 men
were deemed treatment failures. Three men had more than
one complication; thus, there were 13 urethral strictures;
2 bladder neck contractures, 4 recurrent BPH, and three
detrusor failures (Table 1). This left 72 men providing long-
term TURP outcome data.
Thea v erageageatoperationwas67yearsandatfollo wup
was 72 years (range 57–94yr). Mean follow-up time was 70
months (range 36–98 months). Twenty men (22%) were in
acute urinary retention before the operation.
Baseline parameters were not available in all areas for
all 72 men. Voiding parameters were also not available for
men in acute retention. Of the available data, the mean
baseline results and number of men which contributed to it
are given in Table 2. The mean results were IPSS 21; QoL 4;
Qmax 8mL/s; VV 247mL; PVR 205mL; PSA 6.5.
Most patients had undergone TURP using monopolar
diathermy and a 26F continuous ﬂow resectoscope. If
prolonged resection time had been anticipated (i.e., large or
inﬂamed prostate), a bipolar Gyrus diathermy device had
been used.
Clopidogrel and/or warfarin (but not aspirin) had been
ceased before surgery. Operations were performed either
under general anaesthesia or spinal anaesthesia. 1.5% glycine
was used for irrigation unless the Gyrus diathermy was used,
in which case normal saline was the irrigation ﬂuid. All
patients received antibiotic cover on induction. All patients
had an irrigation catheter inserted and continuous bladder
irrigation (CBI) commenced. In those considered high risk
of detrusor failure, a suprapubic catheter had also been
inserted. Mean resection weight was 26g (range 6–75g).
Overall at long-term review the mean follow-up IPSS
was 7. This is an improvement from baseline of 14 points
(Table 3). Paired results were available for 39 men. For
these, IPSS changed from 21 (±6.0) at baseline to 7 (±6.5)
at followup—an improvement of 67% (Table 4). This is
signiﬁcantundertheWilcoxon’ssignedranktest(P<0.001).
Quality of life was improved from baseline, with
the average follow-up QoL score being 1.5 (Table 3).Advances in Urology 3
Table 2: Baseline characteristics for men undergoing TURP.
Parameter Value
Age
Number 91
Mean 67
Range 50–88
Questionnaires
IPSS
Number 61
Mean 21
Range 5–35
QoL
Number 64
Mean 4
Range 3–6
Flowmetry
Qmax
Number 58
Mean (mL/s) 8
Range 3–18
VV
Number 57
Mean (mL) 247
Range 125–576
PVR
Number 49
Mean (mL) 205
Range 15–720
Prostate measure
PSA
Number 62
Mean 6.5
Range 0.6–29
Resection weight
Number 72
Mean 26
Range 6–75
Table 3: Overall long-term outcome results post-TURP.
Parameter Initial Followup Diﬀerence % Improvement
IPSS 21 7 14 67%
QoL 4 1.5 2.5 63%
PGI-I 0.9
Qmax 8 22 14 175%
VV 247 424 177 72%
PVR 205 65 140 68%
39 men provided paired QoL scores. For them, there was
a signiﬁcant improvement from the initial preoperative 4
(±1.2) to 1.5 (±1.4) (P<0.001) (Table 4).
The PGI-I question was answered by 67 patients. The
meanscorewas0.9(±1.3),andnoneratedtheirurinarytract
condition as unchanged or worse. The median response was
0.
Table 4: Paired long-term outcome results post-TURP.
Parameter n Initial Followup Diﬀerence (%) P
IPSS 39 21 7 14 (67%) <0.001
QoL 39 4 1.5 2.5 (63%) <0.001
Qmax 27 8 23 15 (187%) <0.001
VV 27 249 421 172 (69%) <0.001
PVR 25 220 45 175 (80%) <0.001
Initial baseline voiding parameters showed a mean ﬂow
rate of 8mL/s with a voided volume of 247mL and postvoid
residual of 205mL. A valid follow-up measurement was
available for 43 men. For these men, the mean Qmax was
22mL/s (±7.6mL/s). VV was 424mL, and PVR was 65mL
(Table 3).
Paired data was available for 27 men. Signiﬁcant
improvement was recorded in all three parameters at
followup. For the paired data, the average ﬂow rate at
followupwas23mL/s,muchimprovedovertheinitial8mL/s
(P<0.001) (Table 3). This improvement in ﬂow rate of
15mL/s equates to an almost threefold increase.
For these 27 men, the voided volume also remained
i m p r o v e dw i t ham e a no f4 2 1 m L( ±180.6mL) at review
compared to the baseline of 249mL (Table 4). This is a 69%
improvement. Improvement in PVR was also observed with
an overall long-term mean value of 45mL, signiﬁcantly bet-
ter than the mean preoperative PVR of 220mL (P<0.001).
Of the 72 long-term follow-up patients, 43 of them were
asked about sexual function. Of these 43 men, 13 (30%)
stated they were not sexually active. Of the remaining 30
patients, who regarded themselves as active, the mean IIEF-
5s c o r ew a s1 5( ±7). No patient had completed a preoper-
ative IIEF-5 questionnaire. Absence of seminal emission on
orgasm was reported in 26 (87%) of these 30 men, while 2
(7%) maintained antegrade ejaculation and another 2 were
unsure.
4. Discussion
In this study, of the potential 210 patients who underwent
TURP over the 6 year period, 91 patients participated in
long-term follow-up assessment. 119 men were excluded: 24
were not primary TURPs, 41 had a urological cancer, 19 had
died, 24 were lost to followup, and 11 were unwilling or
unable to participate. During this period of time examined,
no competing form of BPH surgery was oﬀered, including
any clinical trials of new technology. With the introduction
of photoselective vaporisation of the prostate (PVP) into this
urological practice in 2005, TURP was no longer routinely
oﬀered.
The average follow-up time was just under 6 years
(70 months) with a range of 3–8 years. Of the 91 men
participating, 19 were deemed treatment failures requiring
reintervention. This left 72 men providing long-term out-
come data.
Follow-up parameters included both subjective out-
comes assessed by validated questionnaires and objective
ﬂowmetry data with voided volume and postvoid residual.
When possible, paired data was analysed.4 Advances in Urology
This study found that IPSS was improved on the
long term. The average decrease in IPSS was 14 points,
representing a 67% reduction in symptoms. The majority
of men, at followup, regarded their urinary symptoms as
being mild (IPSS score 7–9). This compared to preoperative
assessment where the majority reported their symptoms as
severe (IPSS 20–35). This improvement in IPSS is similar
to other reports which give a score between 6 and 7.7 after
3–7-year followup [8, 13–16]. These studies, however, used
TURP as a control arm in a comparison study rather than
lookingatthe“average”TURPpatientasthisstudyhasdone.
Not surprisingly, the improvement in lower urinary tract
symptoms is mirrored in the quality of life and patient
global impression of improvement scores. Most men initially
reported they were “mostly dissatisﬁed” (QoL score of 4)
with their symptoms but this improved, and, at followup,
they regarded themselves as “pleased” to “mostly satisﬁed”
(QoL score of 1-2). The PGI-1 score, which asked men to
compare their current situation to that before the operation,
had most men answering “very much better.” This correlated
with a median score of zero. No man recorded an unchanged
or worse score.
Long-term improvement in ﬂow rate, voided volume,
and postvoid residual was also found in this study. Paired
data showed an average postoperative ﬂow rate of 23mL/s,
with an average increase in ﬂow rate of 15mL/s. This
increase in ﬂow rate is one of the highest reported with the
average expected improvement in ﬂow rate typically around
10mL/s [17]. Voided volume and postvoid residual were also
improved by 69% and 80%, respectively.
Atreview,43menwereaskedabouttheirsexualfunction.
Interestingly,30%ofmenstatedtheywerenotsexuallyactive
and so did not complete the IIEF-5 questionnaire. Of the 30
men who did complete this questionnaire, the average score
was 15. Unfortunately no baseline data was available to allow
postoperative changes to be calculated. This result, however,
can be compared to the general population. Several studies
have demonstrated that up to 80% of men over 70 years
o fa g eh a v ead e g r e eo fs e x u a ld y s f u n c t i o n[ 18, 19]. While
the data in this series is limited, it does suggest that TURP
has had no long-term eﬀect on erectile function. It does,
however, have a signiﬁcant impact on antegrade emission.
87% of sexually active men reported loss of emission on
orgasm at followup. This ﬁnding is similar to most other
reports.
19 (21%) of the 91 men eligible for review were regarded
as treatment failures. Of these 19 men, only four (4%) had
recurrent BPH as the cause of their recurrent symptoms.
The remaining 15 men required intervention for other
causes: 14% for urethral strictures and 2% for bladder neck
contractors. While this reintervention rate appears high, it
is important to note that this ﬁgure may be artiﬁcially high.
145 men were initially eligible to participate in this study
but were excluded due to death (19), lost to follow up (24),
or unwilling/able to participate (11). The reintervention rate
therefore is somewhere between 13–21%.
An important clinical distinction exists between rein-
tervention due to prostatic regrowth and due to other
complications. This study found that the rate of prostatic
regrowth requiring redoing TURP was low, at only 4%,
which equates to 0.5% per year. This result is on the lower
end of results quoted in the literature which range from 3–
15% at 5 years [6]. This is most likely a reﬂection on the
volume of tissue resected, which for this study was 26g. This
resection volume is consistent with other published series
with an average resection volume of 15–29 g [5, 20–23].
The reintervention rate for urethral strictures identiﬁed
in this study is somewhere between 9–14%. Compared to
the incidence of strictures quoted in the literature (2–10%
[6]), this rate is high. The development of a urethral stricture
is most likely secondary to instrumentation, technique, or
postoperative catheterisation. In this study, all operations
were conducted using a 26F continuous resectoscope. The
advantages of using a larger, continuous ﬂow, resection
sheath are improved irrigation and vision with lower
irrigation pressures. This contributes to better haemostasis
hence the absence of blood transfusion and the absence
of TUR syndrome observed in this study. The use of this
large sheath is likely to have helped contribute to the
higher resection volume identiﬁed in this study. A higher
stricture rate associated with larger resection sheaths has
however previously been reported [24, 25], and this appears
to hold true for this series. Identiﬁcation of this increased
risk however does not translate into the need to abandon
their use. Suggestion has been made that routine urethral
dilation prior to insertion of the resection sheath may reduce
this incidence. Other factors have also been suggested in
the literature as contributing to an increased incidence of
urethral strictures. These include a high cutting current and
use of lubrication [6]. Lowering the ﬁrst and increasing
the second are thought to help minimise stricture rate.
The degree to which each of these factors inﬂuences the
stricture rate is unknown, but most suggestions can be easily
implementedwithminimalimpositionorsideeﬀects.Repeat
long-term review is then warranted to clarify if these factors
helpreducethiscomplicationrate.Asthiswasaretrospective
analysis,thehighstrictureratewasnotpreviouslyrecognised
and able to be addressed prior to the introduction of PVP
which replaced the use of TURP in this urological practice.
There are several short comings with this study. Firstly,
this study only compared a subject’s voiding symptoms at
two points, baseline, and followup, this prevents any attempt
to predict an expected projectory. Currently, the literature
also does not help in predicting very long-term results. On
one hand, a slow decline may be expected. When looking
at intermediate (∼3 year) studies and comparing them to
long-term (>4 year) studies, an increase in IPSS score is
observed, with intermediate studies having an IPSS range of
3t o1 0[ 8, 16, 26], while longer-term studies have a range
o f6t o1 1[ 15, 27, 28]. On the other hand, other studies like
Mishriki et al. found the mean IPSS at 6 years was 10 but this
impr ov edto8.5at12years[29].Itisimportanttoremember,
however, that changes in voiding symptoms overtime may be
better explained in terms of the normal aging process rather
than a function of their prostatic disease or an eﬀect of the
surgery [12].
Another short coming of this study is that it is a retro-
spective study incorporating only a single surgeon’s results.Advances in Urology 5
This limitation is minimised by comparing these results to
those currently published.
Despite these shortcomings, an overall durable sig-
niﬁcant improvement in subjective as well as objective
parameters has been shown after a long-term followup of
TURP. These results contribute to the objective of setting
a standard that other interventions must meet before an
alternative“goldstandard”forsymptomatic benignprostatic
hyperplasiacanbeintroduced.However,diﬀerencesbetween
studies in patient numbers, statistical analyses, inclusion,
and exclusion criteria and follow-up periods have shown
that a clear protocol should be made for similar follow-
up studies in order to make good comparisons possible.
In our opinion, the PGI-I question should be included as
one of those standards. In order to avoid timeframe-based
diﬀerences, only recent studies should be used in assessing
the long-term followup of TURP.
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